Research
Hormonal
Designer drugs using mono, dual, and triple agonists of GLP-1, GIP, and glucagon can promote weight loss without effort.
Practitioners may consider these drugs as potential options for patients struggling with obesity.
StrongSupportsmedium confidence
Now there are designer drugs that seem to accomplish the task: we can lose weight without effort using mono, dual, and triple agonists of receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon.
Why this rating
The abstract discusses a significant advancement in obesity treatment.
Source
GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective
Mateus d’Ávila et al. · Endocrinology · 2024
DOI 10.1210/endocr/bqae128
otherCited 11×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →